Xofigo
| Chemical Name | radium Ra 223 dichloride |
| Dosage Form | Injection (intravenous; 1,100 kBq/mL (30 microcurie/mL)) |
| Drug Class | Radioactive therapeutic agents |
| System | Male reproductive, Musculoskeletal |
| Company | Bayer |
| Approval Year | 2013 |
Indication
- For the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.